As per MRFR analysis, the Glioblastoma Multiforme Market Size was estimated at 2.94 (USD Billion) in 2024. The Glioblastoma Multiforme Market Industry is expected to grow from 3.19 (USD Billion) in 2025 to 6.66 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.52% during the forecast period (2025 - 2034).
The increasing incidence of glioblastoma multiforme globally, rising healthcare infrastructure, and increased awareness, and access to advanced therapies are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain cancer. According to statistics provided by the Centers for Disease Control and Prevention (CDC), a national public health body of the US in 2022, about 90% of adult GBM patients pass away within 24 months of their diagnosis. According to American Association of Neurological Surgeons reported that in June 2021, glioblastoma represented 47.7% of all cases of malignant brain and CNS tumors. Glioblastoma affects 3.21 out of every 100,000 people. Moreover, the median age at diagnosis is 64, and men are more likely than women to obtain a diagnosis.
The figures above indicate that the need for therapies is expected to increase dramatically, which is anticipated to drive the global market for glioblastoma multiforme (GBM) treatments. Complex factors, such as aging populations, overdiagnosis, ionizing radiation, air pollution, and other factors, are the key reason for development of Glioblastoma multiforme. Furthermore, it is anticipated that the market for glioblastoma multiforme (GBM) treatments will be driven by the increase in cases of brain and other nervous system cancers across the world. However, it has been discovered that people with GBM have a rather low survival rate.
The Market segments of Glioblastoma Multiforme, based on treatment type, includes surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field (TTF) therapy, and others. The radiation therapy segment is held the majority share in 2022 in the Glioblastoma Multiforme Market revenue. This is due to the technological breakthroughs in radiotherapy and improved survival rates. Additionally, radiation therapy is another highly demanded option, especially for patients who are not suitable candidates for surgery. In case of recurrence, it is also effective and strongly advised for brain tumors. Thus, the increasing acceptability of this surgical technique for treating brain tumors is fueling the global segment's expansion.
December 2020: Bristol-Myers Squibb Company (US) has released an update on the Phase 3 CheckMate -548 trial, which compares Opdivo (nivolumab) with the standard of care (temozolomide and radiation therapy) in patients with newly diagnosed glioblastoma multiforme (GBM) with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation after surgical resection of the tumor to placebo plus the standard of care.
Figure 2: GLIOBLASTOMA MULTIFORME MARKET, BY TREATMENT TYPE, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Glioblastoma Multiforme Market segmentation is based on the end user type that includes hospitals & clinics, ambulatory surgical centers, and others. The hospitals and clinics segment has dominated the market in 2022 and ambulatory surgical centers is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to hospitals are preferred by patients in terms of treatment accessibility and convenience and they are equipped with the necessary infrastructure for diagnosis and treatment. Furthermore, it is projected that the complexity of the treatment and the large number of procedures required to manage glioblastoma multiforme (GBM) will propel the segment’s growth.
November 2021: GenScript (US) expanded manufacturing capabilities for glioblastoma multiforme in the USA. With this expansion, GenScript will be able to synthesize 200 genes per day in a fully automated facility, serving more clients and completing more difficult gene projects. With an increased capacity to synthesize 4,000–5,000 genes per month in the US, this new facility provides a much-improved capacity to manage large glioblastoma multiforme projects.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American glioblastoma multiforme market accounted for the largest market share in 2022. This is attributed to the robust healthcare infrastructure, substantial R&D investments, and a high prevalence of the disease. Additionally, along with expanding government support for disease treatment programs and awareness campaigns, the FDA is increasingly approving new pharmaceuticals for the market.
Further, the major countries studied are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Figure 3: GLIOBLASTOMA MULTIFORME MARKET BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe glioblastoma multiforme market is expected to account for the second-largest market share due to the increased focus on early diagnosis and multidisciplinary care of disease in the region. Further, the Germany market of glioblastoma multiforme was attributed to holding the largest market share, and the UK market of glioblastoma multiforme is expected to fastest-growing market in the European region.
The Asia-Pacific glioblastoma multiforme market is expected to grow at the fastest rate from 2023 to 2032. This is due to the growing patient population and expanding healthcare infrastructure in the Asia-pacific region. Moreover, China’s market of glioblastoma multiforme is expected to hold the largest market share, and India market of glioblastoma multiforme is expected fastest-growing market in the Asia-Pacific region.
Furthermore, the Asia-Pacific region immunotherapy is a major trend, with several countries offering it as a treatment option. However, access to advanced treatments varies across Asia-Pacific nations, with disparities in healthcare resources and affordability which is expected to accelerate market growth in the glioblastoma multiforme.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of glioblastoma multiforme in the Middle East and Africa are the increase in cases of brain and other nervous system cancers and rise in awareness about chemotherapy treatment in the region that boost the market growth in the Middle East. Moreover. In order to meet unmet medical requirements, international partnerships are investigating ways to increase access to care in these regions. Despite obstacles, glioblastoma multiforme is receiving more attention globally, which is gradually changing the landscape and giving hope to patients in these underdeveloped locations.
The Market of Glioblastoma Multiforme is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Merck & Co., Inc (US), Amgen, Inc (US), Bristol-Myers Squibb Company (US), and F. Hoffmann-La Roche Ltd (Switzerland) dominate the market of Glioblastoma Multiforme due to product differentiation, financial stability, strategic developments, and diversified regional presence.
The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base. One of the primary business strategies adopted by manufacturers in the global glioblastoma multiforme industry to benefit clients and expand the glioblastoma multiforme market sector is to manufacture locally to reduce operating costs.
Merck & Co., Inc (US) is one of the leading global biopharmaceutical companies that develop prescription medicines, vaccines, biologic therapies, and animal health products. It operates in more than 140 countries to deliver innovative health solutions. It operates through pharmaceutical, animal health, and healthcare services segments. The pharmaceutical segment includes human health pharmaceutical and vaccine products. The animal health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment, and control of diseases in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers.
The healthcare services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. For instance, in May 2019, Merck & Co., Inc. (US) acquired Peloton Therapeutics (US) to expand its pipeline of potential cancer treatments. which allows it access to the glioblastoma drug PT2977, which is still an investigational drug. This acquisition will strengthen its pipeline and expand its potential to make money in the future.
Also, F. Hoffmann-La Roche Ltd. (Roche) (Switzerland) manufactures medications and diagnostic tools to combat serious diseases. It creates and sells products for the detection and treatment of autoimmune disorders, cancer, chlamydia, dermatology, gonorrhea, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, cardiovascular diseases, diabetes, central nervous system, and hemostasis disorders.
The company supplies in-vitro diagnostics and drugs for cancer and transplantation. Moreover, it specializes in the field of molecular diagnostics and medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. In addition, the company has offices and subsidiaries throughout the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
UNC Health is currently recruiting people for a multicenter clinical research aimed at individuals who have just been diagnosed with glioblastoma (GBM). The phase 2b clinical trial involves administering IGV-001, a combined immunotherapy created by the biotechnology company Imvax. UNC Health is one of several academic healthcare facilities nationwide involved in a randomized experiment. The trial's objective is to recruit 93 people who have recently been diagnosed with brain tumors.
UNC Health will establish 14 satellite sites across North Carolina, in addition to its flagship campus in Chapel Hill. These sites will enable patients residing far from Chapel Hill to undergo assessment and potentially participate in the study. If patients are enrolled in the trial, they will continue to receive weekly treatments at UNC Hospitals in Chapel Hill, NC. The trial aims to evaluate the safety and effectiveness of a combined immunotherapy treatment for individuals who have recently been diagnosed with glioblastoma. The multicenter trial is a Phase 2b study that is randomized, double-blind, and placebo-controlled. Following the surgical removal of the tumor at UNC Health, individuals participating in the study will have miniature biodiffusion chambers implanted in their bodies for around 48 hours. These chambers will contain either IGV-001, a substance specifically created to stimulate a comprehensive and long-lasting immune response against cancers, or a placebo.
March 2024: A joint endeavor aimed at delivering the potential of cell therapy to individuals suffering from a lethal type of brain cancer has demonstrated remarkable outcomes in the initial group of patients who underwent the innovative treatment. A recent publication in The New England Journal of Medicine presented findings from a phase 1 clinical trial conducted by researchers at the Mass General Cancer Center, which is part of the Mass General Brigham healthcare system.
The study focused on evaluating a novel CAR-T therapy for glioblastoma (GBM) and reported the results of the first three patient cases. The INCIPIENT trial aims to assess the safety of CARv3-TEAM-E T cells in individuals with recurrent GBM. Within a few days of receiving a single therapy, patients observed significant decreases in the size of their tumors, and one patient even achieved almost full disappearance of the tumor. Over time, the researchers witnessed the advancement of tumors in these individuals. However, due to the encouraging first outcomes of the procedure, the team will now focus on implementing methods to prolong the effectiveness of the treatment.
July 2019: Amgen, Inc (US) and Allergan plc (Ireland) have announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), is now available in the United States (U.S.). This launch will result in an increase in the product's sales in the region.
June 2019: The US Food and Drug Administration (FDA) has approved Zirabev, a Pfizer biosimilar of Avastin for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic renal cell carcinoma, recurrent glioblastoma multiforme, and metastatic cervical cancer.
| Report Attribute/Metric | Details |
| Market Size 2024 | Â Â 2.94 (USD Billion) |
| Market Size 2025 | Â Â 3.19 (USD Billion) |
| Market Size 2034 | Â Â 6.66 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | Â Â 8.52 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment Type and End User Type, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Merck & Co., Inc (US), Amgen, Inc (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc (US), AstraZeneca (UK), Eli Lilly and Company (US), VBI Vaccines Inc. (US), and AbbVie Inc (US) |
| Key Market Opportunities | ·      Advances in medical technology and a deeper understanding of the disease |
| Key Market Dynamics | ·      Increasing incidence of glioblastoma multiforme globally ·      Rising healthcare infrastructure ·      Increased awareness, and access to advanced therapies |
Glioblastoma Multiforme Market Highlights:
Frequently Asked Questions (FAQ) :
The Glioblastoma Multiforme Market is anticipated to reach 5.65 billion during the forecast period of 2023-2032.
The US is expected to hold a 70-80% share of the North American market for the glioblastoma multiforme market during the forecast period of 2023-2032.
The glioblastoma multiforme market is expected to grow at an 8.52% CAGR during the forecast period from 2023 to 2032.
The North America region market held the largest market share in the glioblastoma multiforme market.
The key players include Merck & Co., Inc (US), Amgen, Inc (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc (US), AstraZeneca (UK), Eli Lilly and Company (US), VBI Vaccines Inc. (US), and AbbVie Inc. (US) are the top key players in the glioblastoma multiforme market.
The radiation therapy segment was estimated to lead the glioblastoma multiforme market.
The hospitals & clinics segment is attributed to having the largest market share based on end user.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
